Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pamrevlumab plus corticosteroids in non-ambulatory Duchenne muscular dystrophy
NL-OMON54339Phase 3Active, not recruiting
- Sponsor
- FibroGen
- Start
- Dec 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Duchenne muscular dystrophy (DMD) comparing Pamrevlumab + systemic corticosteroid with Placebo + systemic corticosteroid (2 arms). Primary endpoint: Change in total Performance of Upper Limb 2.0 score. Started Dec 2021; status: active, not recruiting.
02
Drugs
pamrevlumab
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NL-OMON54339.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54339.